Since we have proved two ANO1 inhibitors (CAI/BBR) were feasible for GI cancer cell lines/CDXs/PDXs, their safety and effectiveness in clinical applications deserved to be investigated, and other inhibitors with higher ANO1‐targeted specificity and tumor killing effectiveness should also be developed by future studies. Here, ANO1 is linked to neoplasm.